HighLife
HighLife Medical develops a transcatheter mitral-valve replacement system designed to treat patients with severe mitral regurgitation without open-heart surgery.
€80MFinancing round
LeadME
Mérieux Equity Partners
Activity from announced rounds
Activity in this selectionrialto-venture-capital-8865d6c3
- Rounds participated in
- 2
- Confirmed lead rounds
- 1 All roles disclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $101.3M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionAmyl Therapeutics
Amyl Therapeutics is developing immunotherapies that target amyloid aggregates linked to neurodegenerative disease.
€8.3MSeries A extension
Participant